What we do.
Starton Therapeutics is a clinical-stage biotechnology company focused on improving standard-of-care therapies with our proprietary delivery technology platform to achieve superior outcomes. We seek to improve patient outcomes by optimizing the delivery of FDA-approved medicines, with an initial focus on blood cancers.
At Starton Therapeutics, we believe that how a drug is delivered is as vital as the molecule itself.
Conventional oral cancer therapies often release medication in sudden, intense spikes. These high peak blood levels (Cmax) drive severe, dose-limiting toxicities, such as severe neutropenia and bone marrow suppression, that force treatment interruptions, dose reductions, or discontinuations.
Through our proprietary Temporal Controlled Pharmacology (TCP) platform, we establish exposure pattern over time as an independent biological variable. By precisely controlling the rate and duration of drug delivery, we maintain engagement of the biologic target, optimize therapeutic outcomes, eliminate peak-driven toxicity, and unlock the full potential of proven cancer-fighting therapies without altering their molecular structures.
Latest News
